In a world where the desire for quick fixes and instant results is all too common, it’s no surprise that the weight loss industry is constantly evolving. The promise of a slimmer, healthier body with minimal effort is undoubtedly tempting, leading many to explore new weight loss drugs as a potential solution. However, the dangers associated with these drugs are often underestimated or overlooked. Popular semaglutide injectable  Ozempic will now have a warning about intestinal blockage after the Food and Drug Administration accepted manufacturer Novo Nordisk’s proposed changes to the drug’s packaging.